Quick-Med Technologies, Inc. — Department of Defense SBIR Phase I: AF193-CSO1
Quick-Med Technologies, Inc. — SBIR Phase I award from Department of Defense.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Defense in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $49,982. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code AF193-CSO1 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $49,982
- Agency
- Department of Defense · Air Force
- Program / Phase
- SBIR · Phase I
- Topic
- AF193-CSO1
- Solicitation
- DoD SBIR X19.2
- NAICS
- —
- Place of performance
- FL
- Period
- 2019-12-12 → 2020-12-12
Description
Quick-Med Technologies, Inc. (Gainesville, FL) is an innovative life sciences company specializing in the development of next-generation antimicrobial technologies for the healthcare, consumer, and Government markets. Quick-Med (QMT) has developed the world's most advanced antimicrobial technologies that combat microbial growth in a variety of broad-based products. Our technology is always designed to be safe for the environment and public health. By utilizing biomimetic chemistries, broad and long-lasting antimicrobial efficacy can be provided at affordable cost, without concern about bacterial resistance, or environmental toxicity.